HARMONY BIOSCIENCES HOLDINGS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $9.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $9.34M, a 18.51% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.62M, a 15.03% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $9.97M, a 0.99% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $10.97M, a 0.72% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $44.90M, a 5.38% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $42.60M, a 34.37% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $31.70M, a 21.14% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $26.17M, a 67.14% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.34M 10-Q · filed 2026-08-04 | $19.95M 10-Q · filed 2026-08-04 | $29.93M derived: sum of 3 quarters · filed 2026-08-04 | $40.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $10.62M 10-Q · filed 2026-05-07 | $20.59M derived: sum of 2 quarters · filed 2026-05-07 | $31.56M derived: sum of 3 quarters · filed 2026-05-07 | $43.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $9.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $20.94M derived: sum of 2 quarters · filed 2026-02-24 | $32.40M derived: sum of 3 quarters · filed 2026-08-04 | $44.90M 10-K · filed 2026-02-24 |
| 2025-09-30 | $10.97M 10-Q · filed 2025-11-04 | $22.43M derived: sum of 2 quarters · filed 2026-08-04 | $34.92M 10-Q · filed 2025-11-04 | $45.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $11.46M 10-Q · filed 2026-08-04 | $23.95M 10-Q · filed 2026-08-04 | $34.03M derived: sum of 3 quarters · filed 2026-08-04 | $45.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $12.50M 10-Q · filed 2026-05-07 | $22.57M derived: sum of 2 quarters · filed 2026-05-07 | $33.62M derived: sum of 3 quarters · filed 2026-05-07 | $44.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $21.12M derived: sum of 2 quarters · filed 2026-02-24 | $32.21M derived: sum of 3 quarters · filed 2026-02-24 | $42.60M 10-K · filed 2026-02-24 |
| 2024-09-30 | $11.05M 10-Q · filed 2025-11-04 | $22.14M derived: sum of 2 quarters · filed 2025-11-04 | $32.53M 10-Q · filed 2025-11-04 | $41.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $11.09M 10-Q · filed 2025-08-05 | $21.48M 10-Q · filed 2025-08-05 | $30.34M derived: sum of 3 quarters · filed 2026-02-24 | $38.34M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $10.39M 10-Q · filed 2025-05-06 | $19.26M derived: sum of 2 quarters · filed 2026-02-24 | $27.25M derived: sum of 3 quarters · filed 2026-02-24 | $34.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $8.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.85M derived: sum of 2 quarters · filed 2026-02-24 | $24.50M derived: sum of 3 quarters · filed 2026-02-24 | $31.70M 10-K · filed 2026-02-24 |
| 2023-09-30 | $7.99M 10-Q · filed 2024-10-29 | $15.64M derived: sum of 2 quarters · filed 2024-10-29 | $22.84M 10-Q · filed 2024-10-29 | $30.10M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $7.65M 10-Q · filed 2024-08-06 | $14.85M 10-Q · filed 2024-08-06 | $22.11M derived: sum of 3 quarters · filed 2025-02-25 | $29.12M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $7.20M 10-Q · filed 2024-04-30 | $14.46M derived: sum of 2 quarters · filed 2025-02-25 | $21.47M derived: sum of 3 quarters · filed 2025-02-25 | $28.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $14.27M derived: sum of 2 quarters · filed 2025-02-25 | $21.54M derived: sum of 3 quarters · filed 2025-02-25 | $26.17M 10-K · filed 2025-02-25 |
| 2022-09-30 | $7.01M 10-Q · filed 2023-10-31 | $14.28M derived: sum of 2 quarters · filed 2023-10-31 | $18.91M 10-Q · filed 2023-10-31 | $23.11M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $7.28M 10-Q · filed 2023-08-01 | $11.91M 10-Q · filed 2023-08-01 | $16.10M derived: sum of 3 quarters · filed 2024-02-22 | $20.36M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $4.63M 10-Q · filed 2023-05-02 | $8.83M derived: sum of 2 quarters · filed 2024-02-22 | $13.08M derived: sum of 3 quarters · filed 2024-02-22 | $16.99M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $8.45M derived: sum of 2 quarters · filed 2024-02-22 | $12.36M derived: sum of 3 quarters · filed 2024-02-22 | $15.66M 10-K · filed 2024-02-22 |
| 2021-09-30 | $4.25M 10-Q · filed 2022-11-01 | $8.16M derived: sum of 2 quarters · filed 2022-11-01 | $11.46M 10-Q · filed 2022-11-01 | $14.28M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $3.91M 10-Q · filed 2022-08-02 | $7.21M 10-Q · filed 2022-08-02 | $10.03M derived: sum of 3 quarters · filed 2023-02-21 | $11.10M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $3.30M 10-Q · filed 2022-05-03 | $6.12M derived: sum of 2 quarters · filed 2023-02-21 | $7.20M derived: sum of 3 quarters · filed 2023-02-21 | $7.63M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $3.90M derived: sum of 2 quarters · filed 2023-02-21 | $4.33M derived: sum of 3 quarters · filed 2023-02-21 | $4.69M 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.07M 10-Q · filed 2021-11-09 | $1.50M derived: sum of 2 quarters · filed 2021-11-09 | $1.87M 10-Q · filed 2021-11-09 | $10.68M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $429.00K 10-Q · filed 2021-08-10 | $797.00K 10-Q · filed 2021-08-10 | $9.60M derived: sum of 3 quarters · filed 2022-02-28 | $10.01M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $368.00K 10-Q · filed 2021-05-11 | $9.17M derived: sum of 2 quarters · filed 2022-02-28 | $9.58M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $9.21M derived: sum of 2 quarters · filed 2022-02-28 | $9.91M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $407.00K 10-Q · filed 2020-11-12 | $1.10M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |